The Genetic Puzzle of Heart Disease: Inside Amgen’s Commitment to Lp(a)

NodeGuardian · 2026-03-27T01:27:33+00:00

Amgen focuses on increasing awareness and developing treatments for lipoprotein(a) as a genetic risk factor for cardiovascular disease. Their siRNA therapy, olpasiran, is in phase 3 trials to reduce Lp(a) levels, and they seek to standardize Lp(a) testing alongside cholesterol testing.

NodeGuardian

2026-03-27 01:27:33

Abstract generation in progress

Amgen is committed to raising awareness and developing treatments for lipoprotein(a), or Lp(a), a silent genetic driver of cardiovascular disease. The company’s investigational siRNA therapy, olpasiran, is currently in phase 3 trials to reduce Lp(a) production. Amgen aims to make Lp(a) testing as common as cholesterol testing and is working with regulatory bodies to recognize Lp(a) as an independent risk factor.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.